Aura Biosciences, Inc. (AURA)
NASDAQ: AURA · IEX Real-Time Price · USD
7.85
+0.15 (1.95%)
At close: Mar 28, 2024, 4:00 PM
7.69
-0.16 (-2.04%)
After-hours: Mar 28, 2024, 5:00 PM EDT
Company Description
Aura Biosciences, Inc. operates as a biotechnology company that develops therapies to treat cancer.
The company develops virus-like drug conjugates (VDC) technology platform for treating tumors of high unmet need in ocular and urologic oncology.
It is developing AU-011, a VDC candidate for the treatment of primary choroidal melanoma that is in phase III clinical trial.
The company also develops AU-011 for additional ocular oncology indications, including choroidal metastases and is in Phase 2 dose-escalation trial.
The company was incorporated in 2009 and is headquartered in Cambridge, Massachusetts.
Aura Biosciences, Inc.
Country | United States |
Founded | 2007 |
IPO Date | Oct 29, 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 70 |
CEO | Dr. Elisabet de los Pinos Ph.D. |
Contact Details
Address: 80 Guest Street Boston, Massachusetts 01235 United States | |
Phone | (617)500-8864 |
Website | aurabiosciences.com |
Stock Details
Ticker Symbol | AURA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $14.00 |
CIK Code | 0001501796 |
CUSIP Number | 05153U107 |
ISIN Number | US05153U1079 |
Employer ID | 32-0271970 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Elisabet de los Pinos Ph.D. | Founder, Chief Executive Officer, President and Director |
Julie B. Feder | Chief Financial Officer, Secretary and Treasurer |
Dr. Mark Plavsic D.V.M., Ph.D. | Chief Technology Officer |
Patrick Nealon | Senior Vice President of Clinical Development Operations |
Dr. Bruce Brown M.D. | Senior Vice President and Therapeutic Area Head of Urologic Oncology |
Dr. Anthony Daniels M.D. | Therapeutic Area Head of Ocular Oncology |
Dr. Richard Mountfield Ph.D. | Senior Vice President of Regulatory Affairs and Quality |
Dr. Jill Hopkins M.D. | Chief Medical Officer and President of Research and Development |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 27, 2024 | S-3 | Registration statement under Securities Act of 1933 |
Mar 27, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Mar 27, 2024 | 10-K | Annual Report |
Mar 27, 2024 | 8-K | Current Report |
Mar 4, 2024 | 144 | Filing |
Feb 23, 2024 | 144 | Filing |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 7, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Jan 24, 2024 | 144 | Filing |
Jan 24, 2024 | 144 | Filing |